# Technology Impact Award

**Funder:** Cancer Research Institute
**Budget:** Up to $600,000 + up to 10% indirect costs
**Deadline:** 15 November 2026 (23:59 Eastern Time; LOI deadline, invited full proposal due 1 March 2027)
**Duration:** 2-4 years
**Consortium:** Optional — clinical cancer immunologists and technology developers are encouraged to collaborate; co-PIs eligible
**Application:** 2-stage: Letter of Intent → invited full proposal
**Frequency:** Annual
**Official call:** https://www.cancerresearch.org/technology-impact-award
**Last updated:** 13 Sept 2026

## Eligibility & scope

Seed funding for early-stage, pre-development technology concepts in cancer immunotherapy; applicants must hold a tenure-track position at a not-for-profit research center or institution. Does not fund clinical trials or refinement of existing technologies.

## Summary

The Technology Impact Award provides up to $600,000 over 2-4 years for early-stage technological innovations in cancer immunotherapy, including computational tools, profiling systems, visualization platforms, culture methods, and novel therapeutic approaches. Applicants must hold tenure-track positions at not-for-profit research institutions; co-PIs are encouraged. The call does not fund clinical trials or development of existing technologies, focusing instead on pre-development stage concepts with innovation potential.

## Who should apply

- Tenure-track researchers at not-for-profit academic or research institutions
- Early-stage technology developers in cancer immunotherapy (computational, profiling, visualization, or culture systems)
- Researchers with genuinely novel or pre-development stage concepts, not incremental advances on existing tools
- Investigators open to multi-PI collaboration; co-PI engagement strengthens applications

## Key dates

- Letter of Intent deadline: 16 November 2026, 23:59 Eastern Time
- Invited full proposal deadline: 12 March 2027
- 2-4 year project duration
- Annual call cycle

## Tips for applicants

- The two-stage format is gating: use the LOI (concise) to demonstrate novelty clearly; full proposals are lengthy and only invited groups advance, so nail the concept first.
- Emphasize why your technology is pre-development or early-stage, not an extension of an existing tool, CRI screens hard for genuine innovation.
- Co-PI letters from collaborators (especially experimental immunologists if your team is computational-heavy, or vice versa) can swing the innovation score.

## Frequently asked questions

### What types of technology innovations does the Cancer Research Institute Technology Impact Award fund?

Early-stage, pre-development innovations in cancer immunotherapy, including computational tools, profiling systems, visualization platforms, culture methods, and novel therapeutics. Clinical trials and continuation of existing technologies are not supported.

### Who is eligible to apply for the Technology Impact Award?

Researchers holding a tenure-track position at a not-for-profit research institution. Co-PIs are encouraged.

### What is the budget range for the Technology Impact Award?

Up to $600,000 over 2-4 years, plus up to 10% indirect costs.

### What is the timeline for the Technology Impact Award application?

Letter of Intent due 16 November 2026 at 23:59 Eastern Time; invited full proposals due 12 March 2027.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/cancer-research-institute-technology-impact-award-2026-11) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.

**See which EU calls match your profile.** [Preview your matches in 30 seconds, no signup](https://grantsby.eu/demo?ref=llm_grant_md).